Clinical Trials Browser

Phase 2 × Cholangiocarcinoma × spartalizumab × Clear all

NCT04866836 2025-03-21

A Study of Tislelizumab Combined With Radiotherapy as the Second-line Treatment of Advanced Biliary Malignant Tumors

Phase 2 Terminated

Gastrointestinal

Cholangiocarcinoma

NCT03779100 2019-01-28

Lenvatinib Plus PD-1 Antibody for Unresectable ICC

Phase 2 Suspended

Gastrointestinal

Cholangiocarcinoma